On June 2, Abivax S.A. declined 25.58% overnight, trading at $98.25/share, with trading volume of $51,100.

On the news front, the company announced results from its Phase 3 maintenance trial evaluating obefazimod in adults with moderately to severely active ulcerative colitis. While the trial met its primary endpoint and both the 25 mg and 50 mg dose groups achieved their respective targets, the market reacted negatively to the data, triggering a sharp sell-off in overnight trading. The decline suggests investors may have found the magnitude of the clinical benefit insufficient relative to elevated expectations following a recent rally driven by strong cash reserve disclosures.

Abivax S.A. is a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases. Its lead candidate obefazimod is in Phase 3 development for ulcerative colitis and is also being developed for Crohn's disease.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)